pyrrolopyrimidine - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	pyrrolopyrimidine	go back to main search page
Accession:	CHEBI:38670	browse the term
Synonyms:	related_synonym:	pyrrolopyrimidines

show annotations for term's descendants Sort by:
Rat (223) Mouse (225) Human (232) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (4) Green Monkey (0) Naked Mole-rat (0) All
Genes (223)

5-iodotubercidin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cyclin-dependent kinase inhibitor 1B

decreases phosphorylation

5-iodotubercidin results in decreased phosphorylation of CDKN1B protein

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

CDC-like kinase 1

decreases activity

5-iodotubercidin results in decreased activity of CLK1 protein

NCBI chr 9:59,947,774...59,959,002
Ensembl chr 9:59,947,764...59,957,000

G

CDC-like kinase 2

decreases activity

5-iodotubercidin results in decreased activity of CLK2 protein

NCBI chr 2:174,570,614...174,582,645
Ensembl chr 2:174,570,653...174,588,985

G

CDC-like kinase 3

decreases activity

5-iodotubercidin results in decreased activity of CLK3 protein

NCBI chr 8:58,152,155...58,167,196
Ensembl chr 8:58,152,155...58,168,181

G

CDC-like kinase 4

decreases activity

5-iodotubercidin results in decreased activity of CLK4 protein

NCBI chr10:35,523,382...35,541,387
Ensembl chr10:35,524,755...35,541,352

G

dual specificity tyrosine phosphorylation regulated kinase 1A

decreases activity

5-iodotubercidin results in decreased activity of DYRK1A protein

NCBI chr11:33,890,706...34,009,420
Ensembl chr11:33,890,490...34,009,420

G

dual specificity tyrosine phosphorylation regulated kinase 1B

decreases activity

5-iodotubercidin results in decreased activity of DYRK1B protein

NCBI chr 1:83,479,168...83,497,011
Ensembl chr 1:83,479,147...83,487,169

G

dual specificity tyrosine phosphorylation regulated kinase 2

decreases activity

5-iodotubercidin results in decreased activity of DYRK2 protein

NCBI chr 7:54,348,724...54,381,363
Ensembl chr 7:54,349,610...54,380,106

G

dual specificity tyrosine phosphorylation regulated kinase 3

decreases activity

5-iodotubercidin results in decreased activity of DYRK3 protein

NCBI chr13:42,594,120...42,604,898
Ensembl chr13:42,594,121...42,604,778

G

dual specificity tyrosine phosphorylation regulated kinase 4

decreases activity

5-iodotubercidin results in decreased activity of DYRK4 protein

NCBI chr 4:159,715,658...159,757,660
Ensembl chr 4:159,715,417...159,757,627

G

insulin 2

increases secretion
affects secretion

5-iodotubercidin results in increased secretion of INS protein
5-iodotubercidin affects the secretion of INS protein

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

matrix metallopeptidase 3

increases expression

5-iodotubercidin results in increased expression of MMP3 mRNA

NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961

G

neurofilament medium chain

increases expression

5-iodotubercidin results in increased expression of NEFM mRNA

NCBI chr15:42,360,449...42,365,753
Ensembl chr15:42,360,454...42,365,755

G

olfactomedin 4

decreases expression

5-iodotubercidin results in decreased expression of OLFM4 mRNA

NCBI chr15:55,385,100...55,429,687
Ensembl chr15:55,407,148...55,429,681

G

regenerating family member 3 beta

decreases expression

5-iodotubercidin results in decreased expression of REG3A mRNA

NCBI chr 4:110,861,775...110,865,015
Ensembl chr 4:110,861,775...110,865,015

G

solute carrier family 2 member 2

increases expression

5-iodotubercidin results in increased expression of SLC2A2 mRNA

NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933

antalarmin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

corticotropin releasing hormone receptor 1

multiple interactions

antalarmin binds to and results in decreased activity of CRHR1 protein

NCBI chr10:89,040,186...89,083,481
Ensembl chr10:89,040,203...89,083,481

G

cytochrome P450, family 11, subfamily a, polypeptide 1

decreases expression

antalarmin results in decreased expression of CYP11A1 mRNA

NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338

G

cytochrome P450, family 17, subfamily a, polypeptide 1

decreases expression

antalarmin results in decreased expression of CYP17A1 mRNA

NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573

G

fatty acid amide hydrolase

multiple interactions

antalarmin inhibits the reaction [Corticosterone results in increased activity of FAAH protein]

NCBI chr 5:129,479,774...129,499,018
Ensembl chr 5:129,479,824...129,498,677

G

steroidogenic acute regulatory protein

decreases expression

antalarmin results in decreased expression of STAR mRNA

NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672

G

sulfotransferase family 2A member 1

decreases expression

antalarmin results in decreased expression of SULT2A1 mRNA

NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134

baricitinib

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AP2 associated kinase 1

decreases activity

baricitinib results in decreased activity of AAK1 protein

NCBI chr 4:119,300,128...119,451,834
Ensembl chr 4:119,295,257...119,450,969

G

C-C motif chemokine ligand 2

multiple interactions

baricitinib inhibits the reaction [OSM protein results in increased expression of CCL2 mRNA]

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

cyclin G associated kinase

decreases activity

baricitinib results in decreased activity of GAK protein

NCBI chr14:1,089,853...1,164,098
Ensembl chr14:1,089,866...1,216,398

G

inhibitor of DNA binding 2

multiple interactions

baricitinib inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in increased expression of ID2 protein]

NCBI chr 6:41,740,556...41,742,393
Ensembl chr 6:41,728,946...41,744,400

G

Janus kinase 1

decreases activity
multiple interactions

baricitinib results in decreased activity of JAK1 protein
baricitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK1 protein]

PMID:23968543 PMID:29687421

NCBI chr 5:115,780,248...115,888,841
Ensembl chr 5:115,780,248...115,888,926

G

Janus kinase 2

decreases activity
multiple interactions

baricitinib results in decreased activity of JAK2 protein
baricitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK2 protein]

PMID:23968543 PMID:29687421

NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189

G

Janus kinase 3

multiple interactions

baricitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK3 protein]

NCBI chr16:18,386,330...18,398,542
Ensembl chr16:18,386,405...18,398,536

G

oncostatin M

multiple interactions

baricitinib inhibits the reaction [OSM protein results in increased expression of CCL2 mRNA]; baricitinib inhibits the reaction [OSM protein results in increased expression of SAA1 mRNA]; baricitinib inhibits the reaction [OSM protein results in increased expression of SAA2 mRNA]; baricitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK1 protein]; baricitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK2 protein]; baricitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK3 protein]

NCBI chr14:79,103,638...79,108,500
Ensembl chr14:79,104,344...79,108,313

G

signal transducer and activator of transcription 1

multiple interactions

baricitinib inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased phosphorylation of STAT1 protein]

NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540

capivasertib

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

increases phosphorylation

capivasertib results in increased phosphorylation of AKT1 protein

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

AKT1 substrate 1

decreases phosphorylation

capivasertib results in decreased phosphorylation of AKT1S1 protein

NCBI chr 1:95,333,186...95,339,678
Ensembl chr 1:95,332,898...95,339,677

G

BCL2 interacting protein 3

multiple interactions

capivasertib affects the reaction [bafilomycin A1 results in increased expression of BNIP3 protein]

NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359

G

caspase 3

multiple interactions

[capivasertib co-treated with Chloroquine] results in increased activity of CASP3 protein; CA 074 methyl ester inhibits the reaction [[capivasertib co-treated with Chloroquine] results in increased activity of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions
increases expression

bafilomycin A1 promotes the reaction [capivasertib results in increased expression of MAP1LC3B protein modified form]

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
Ensembl chr16:49,665,791...49,677,690

G

ribosomal protein L18

multiple interactions

capivasertib inhibits the reaction [sodium arsenite results in increased expression of RPL18 mRNA]; capivasertib inhibits the reaction [sodium arsenite results in increased expression of RPL18 protein]

NCBI chr 1:96,188,811...96,191,452
Ensembl chr 1:96,188,112...96,191,452

G

ribosomal protein S21, pseudogene 1

multiple interactions

capivasertib inhibits the reaction [sodium arsenite results in increased expression of RPS21 mRNA]; capivasertib inhibits the reaction [sodium arsenite results in increased expression of RPS21 protein]

NCBI chr 5:153,387,133...153,387,476
Ensembl chr 5:153,387,176...153,387,427

G

ribosomal protein S6

decreases phosphorylation

capivasertib results in decreased phosphorylation of RPS6 protein

PMID:26853465 PMID:32397857

NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602

G

sequestosome 1

affects expression

capivasertib affects the expression of SQSTM1 protein

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

sterol regulatory element binding transcription factor 1

decreases expression

capivasertib results in decreased expression of SREBF1 protein

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

ubiquitin A-52 residue ribosomal protein fusion product 1

multiple interactions

capivasertib inhibits the reaction [sodium arsenite results in increased expression of UBA52 mRNA]; capivasertib inhibits the reaction [sodium arsenite results in increased expression of UBA52 protein]

NCBI chr16:18,918,614...18,920,807
Ensembl chr16:18,900,616...18,920,807

GSK2656157

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

activating transcription factor 3

multiple interactions

GSK2656157 inhibits the reaction [pegaspargase promotes the reaction [ATF3 protein binds to FGF21 promoter]]

NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631

G

activating transcription factor 4

multiple interactions

GSK2656157 inhibits the reaction [Glucosamine results in increased expression of ATF4 mRNA]; GSK2656157 inhibits the reaction [Palmitic Acid results in increased expression of ATF4 mRNA]; GSK2656157 inhibits the reaction [Palmitic Acid results in increased expression of ATF4 protein]; GSK2656157 inhibits the reaction [pegaspargase promotes the reaction [ATF4 protein binds to FGF21 promoter]]; GSK2656157 inhibits the reaction [perfluorooctanoic acid results in increased expression of ATF4 protein]; GSK2656157 inhibits the reaction [Thapsigargin results in increased expression of ATF4 protein]
GSK2656157 inhibits the reaction [[INS co-treated with Acrylamide] results in increased expression of ATF4 protein]

PMID:30602124 PMID:32578922 PMID:36030031 PMID:38582373 PMID:38604440

NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446

G

BCL2 associated X, apoptosis regulator

multiple interactions

GSK2656157 inhibits the reaction [[INS co-treated with Acrylamide] results in increased expression of BAX protein]

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

DNA-damage inducible transcript 3

multiple interactions

GSK2656157 inhibits the reaction [Palmitic Acid results in increased expression of DDIT3 mRNA]; GSK2656157 inhibits the reaction [Palmitic Acid results in increased expression of DDIT3 protein]
GSK2656157 inhibits the reaction [6-methoxyflavone results in increased expression of DDIT3 protein]
GSK2656157 inhibits the reaction [[INS co-treated with Acrylamide] results in increased expression of DDIT3 protein]

PMID:35400257 PMID:36030031 PMID:38604440

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

eukaryotic translation initiation factor 2A

multiple interactions

GSK2656157 inhibits the reaction [[INS co-treated with Acrylamide] results in increased phosphorylation of EIF2A protein]

NCBI chr 2:142,761,303...142,794,767
Ensembl chr 2:142,761,416...142,795,068

G

eukaryotic translation initiation factor 2 alpha kinase 3

multiple interactions
decreases activity

GSK2656157 promotes the reaction [shikonin inhibits the reaction [Glutamic Acid results in increased phosphorylation of EIF2AK3 protein]]
GSK2656157 inhibits the reaction [6-methoxyflavone results in increased phosphorylation of EIF2AK3 protein]
GSK2656157 results in decreased activity of EIF2AK3 protein

PMID:35028790 PMID:35400257

NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911

G

eukaryotic translation initiation factor 2 subunit alpha

multiple interactions

GSK2656157 inhibits the reaction [Glucosamine results in increased phosphorylation of EIF2S1 protein]; GSK2656157 inhibits the reaction [Palmitic Acid results in increased phosphorylation of EIF2S1 protein]
GSK2656157 promotes the reaction [shikonin inhibits the reaction [Glutamic Acid results in increased phosphorylation of EIF2S1 protein]]
GSK2656157 inhibits the reaction [6-methoxyflavone results in increased phosphorylation of EIF2S1 protein]; GSK2656157 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of EIF2S1 protein]

PMID:30602124 PMID:32357311 PMID:35028790 PMID:35400257 PMID:36030031

NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225

G

fibroblast growth factor 21

multiple interactions

GSK2656157 inhibits the reaction [pegaspargase results in decreased expression of FGF21 mRNA]
GSK2656157 inhibits the reaction [pegaspargase promotes the reaction [ATF3 protein binds to FGF21 promoter]]; GSK2656157 inhibits the reaction [pegaspargase promotes the reaction [ATF4 protein binds to FGF21 promoter]]; GSK2656157 inhibits the reaction [pegaspargase results in decreased expression of FGF21 protein]

NCBI chr 1:96,083,360...96,084,911
Ensembl chr 1:96,083,441...96,090,454

G

forkhead box O1

multiple interactions

GSK2656157 inhibits the reaction [Palmitic Acid results in decreased expression of FOXO1 mRNA]

NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790

G

insulin 2

multiple interactions

GSK2656157 inhibits the reaction [[INS co-treated with Acrylamide] results in increased expression of ATF4 protein]; GSK2656157 inhibits the reaction [[INS co-treated with Acrylamide] results in increased expression of BAX protein]; GSK2656157 inhibits the reaction [[INS co-treated with Acrylamide] results in increased expression of DDIT3 protein]; GSK2656157 inhibits the reaction [[INS co-treated with Acrylamide] results in increased phosphorylation of EIF2A protein]

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

osteocrin

multiple interactions

GSK2656157 inhibits the reaction [Glucosamine results in increased expression of OSTN mRNA]

NCBI chr11:73,442,167...73,478,498
Ensembl chr11:73,442,487...73,468,603

G

poly (ADP-ribose) polymerase 1

multiple interactions

GSK2656157 inhibits the reaction [glyceryl 2-arachidonate results in increased cleavage of PARP1 protein]

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

pemetrexed

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 5

decreases response to substance

ABCC5 protein results in decreased susceptibility to Pemetrexed

NCBI chr11:80,473,809...80,567,257
Ensembl chr11:80,473,872...80,567,253

G

ALK receptor tyrosine kinase

affects response to substance

ALK gene mutant form affects the susceptibility to Pemetrexed

NCBI chr 6:22,879,653...23,599,636
Ensembl chr 6:22,880,625...23,598,034

G

Bcl-2 binding component 3

increases expression
multiple interactions

Pemetrexed results in increased expression of BBC3 protein
xanthohumol promotes the reaction [Pemetrexed results in increased expression of BBC3 protein]

NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509

G

BCL2, apoptosis regulator

multiple interactions

[Cisplatin co-treated with Pemetrexed co-treated with Valproic Acid] results in decreased expression of BCL2 protein; [Cisplatin co-treated with Pemetrexed co-treated with Vorinostat] results in decreased expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

BH3 interacting domain death agonist

multiple interactions

[Cisplatin co-treated with Pemetrexed] results in increased cleavage of BID protein

NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720

G

complement C3

multiple interactions

[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of C3 mRNA; [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of C3 protein

NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429

G

C-C motif chemokine ligand 2

multiple interactions

[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of CCL2 mRNA

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

cyclin D1

multiple interactions

[Cisplatin co-treated with Pemetrexed co-treated with Valproic Acid] results in decreased expression of CCND1 protein; [Cisplatin co-treated with Pemetrexed co-treated with vorinostat] results in decreased expression of CCND1 protein

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

[Cisplatin co-treated with Pemetrexed co-treated with Valproic Acid] results in increased expression of CDKN1A protein; [Cisplatin co-treated with Pemetrexed co-treated with vorinostat] results in increased expression of CDKN1A protein; [Cisplatin co-treated with Pemetrexed] results in increased expression of CDKN1A protein

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

CASP8 and FADD-like apoptosis regulator

decreases response to substance

CFLAR results in decreased susceptibility to Pemetrexed

NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034

G

DNA-damage inducible transcript 3

multiple interactions

DDIT3 mutant form inhibits the reaction [Pemetrexed results in increased expression of TNFRSF10B]

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

dihydrofolate reductase

multiple interactions

[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of DHFR mRNA

NCBI chr 2:23,585,876...23,611,199
Ensembl chr 2:23,586,031...23,613,713

G

ERCC excision repair 1, endonuclease non-catalytic subunit

multiple interactions
decreases expression

Pemetrexed inhibits the reaction [resveratrol results in increased stability of and results in increased expression of ERCC1 mRNA]; Pemetrexed inhibits the reaction [resveratrol results in increased stability of and results in increased expression of ERCC1 protein]
Pemetrexed results in decreased expression of ERCC1 mRNA; Pemetrexed results in decreased expression of ERCC1 protein

NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963

G

Fas cell surface death receptor

increases expression
multiple interactions

Pemetrexed results in increased expression of FAS protein
TP53 protein affects the reaction [Pemetrexed results in increased expression of FAS protein]; TYMS protein inhibits the reaction [Pemetrexed results in increased expression of FAS protein]

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

folylpolyglutamate synthase

increases response to substance

FPGS protein results in increased susceptibility to Pemetrexed

NCBI chr 3:15,972,800...15,993,592
Ensembl chr 3:15,972,800...15,993,563

G

gamma-glutamyl hydrolase

affects response to substance

GGH protein affects the susceptibility to Pemetrexed

NCBI chr 5:33,529,880...33,552,790
Ensembl chr 5:33,529,880...33,552,787

G

IFI30, lysosomal thiol reductase

multiple interactions

[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IFI30 mRNA

NCBI chr16:18,675,590...18,679,655
Ensembl chr16:18,675,613...18,681,175

G

interleukin 11

multiple interactions

[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL11 mRNA

NCBI chr 1:69,069,829...69,076,129
Ensembl chr 1:69,068,137...69,076,129

G

interleukin 13 receptor subunit alpha 2

multiple interactions

[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL13RA2 mRNA

NCBI chr X:111,002,590...111,074,053
Ensembl chr X:111,002,592...111,072,381

G

interleukin 1 alpha

multiple interactions

[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL1A mRNA

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 receptor-like 1

multiple interactions

[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL1RL1 mRNA

NCBI chr 9:42,661,694...42,727,266
Ensembl chr 9:42,697,192...42,727,256

G

interleukin 33

multiple interactions

[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL33 mRNA

NCBI chr 1:227,701,964...227,736,374
Ensembl chr 1:227,721,435...227,736,373

G

interleukin 7 receptor

multiple interactions

[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL7R mRNA

NCBI chr 2:58,452,393...58,477,757
Ensembl chr 2:58,454,217...58,477,757

G

killer cell lectin like receptor C1

multiple interactions

[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of KLRC1 mRNA

NCBI chr 4:163,142,142...163,152,425
Ensembl chr 4:163,147,189...163,152,425

G

KRAS proto-oncogene, GTPase

decreases expression
increases response to substance

Pemetrexed results in decreased expression of KRAS mRNA; Pemetrexed results in decreased expression of KRAS mRNA mutant form; Pemetrexed results in decreased expression of KRAS protein
KRAS gene mutant form results in increased susceptibility to Pemetrexed

NCBI chr 4:178,185,418...178,218,484

G

methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase

increases response to substance

MTHFD2 protein results in increased susceptibility to Pemetrexed

NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608

G

nucleophosmin 1

decreases response to substance

NPM1 protein results in decreased susceptibility to Pemetrexed

NCBI chr10:17,741,512...17,751,626
Ensembl chr10:17,739,941...17,751,645
Ensembl chr X:17,739,941...17,751,645

G

NRAS proto-oncogene, GTPase

increases response to substance

NRAS gene mutant form results in increased susceptibility to Pemetrexed

NCBI chr 2:190,582,885...190,593,509
Ensembl chr 2:190,582,918...190,591,626

G

RNA binding motif protein 17

decreases response to substance

RBM17 protein results in decreased susceptibility to Pemetrexed

NCBI chr17:66,937,140...66,954,034
Ensembl chr17:66,937,140...66,954,014

G

solute carrier family 19 member 1

multiple interactions
increases response to substance

Pemetrexed inhibits the reaction [SLC19A1 protein results in increased transport of Methotrexate]
SLC19A1 exon mutant form results in increased susceptibility to Pemetrexed

PMID:16505119 PMID:21879757

NCBI chr20:11,584,410...11,602,429
Ensembl chr20:11,584,411...11,601,972

G

solute carrier family 46 member 1

multiple interactions
increases activity
increases response to substance

Pemetrexed inhibits the reaction [SLC46A1 protein results in increased uptake of Methotrexate]
Pemetrexed results in increased activity of SLC46A1 protein
SLC46A1 protein results in increased susceptibility to Pemetrexed

NCBI chr10:63,361,504...63,367,940
Ensembl chr10:63,361,486...63,368,848

G

TNF alpha induced protein 3

multiple interactions

[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of TNFAIP3 mRNA

NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282

G

TNF receptor superfamily member 9

multiple interactions

[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of TNFRSF9 mRNA

NCBI chr 5:161,381,662...161,408,003
Ensembl chr 5:161,381,662...161,408,000

G

tumor protein p53

multiple interactions
affects response to substance

TP53 protein affects the reaction [Pemetrexed results in increased expression of FAS protein]
TP53 protein affects the susceptibility to Pemetrexed

PMID:15161716 PMID:17339891

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

TNF receptor-associated factor 1

multiple interactions

[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of TRAF1 mRNA

NCBI chr 3:18,222,024...18,242,163
Ensembl chr 3:18,222,054...18,241,807

G

thymidine phosphorylase

increases response to substance

TYMP protein results in increased susceptibility to Pemetrexed

NCBI chr 7:120,438,768...120,444,088
Ensembl chr 7:120,438,770...120,443,874
Ensembl chr 7:120,438,770...120,443,874

G

thymidylate synthetase

decreases activity
multiple interactions
affects response to substance

Pemetrexed results in decreased activity of TYMS protein
TYMS protein inhibits the reaction [Pemetrexed results in increased expression of FAS protein]
TYMS affects the susceptibility to Pemetrexed; TYMS protein affects the susceptibility to Pemetrexed

PMID:15161716 PMID:17339891 PMID:21742432

NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536

pevonedistat

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

Bcl-2 binding component 3

affects expression

pevonedistat affects the expression of BBC3 mRNA

NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509

G

BCL2, apoptosis regulator

affects expression

pevonedistat affects the expression of BCL2 mRNA

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

affects expression

pevonedistat affects the expression of BCL2L1 mRNA

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479

G

Bcl2-like 11

affects expression

pevonedistat affects the expression of BCL2L11 mRNA; pevonedistat affects the expression of BCL2L11 protein

NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068

G

caspase 3

multiple interactions

pevonedistat inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]; pevonedistat inhibits the reaction [Cisplatin results in increased expression of CASP3 mRNA]; pevonedistat results in increased cleavage of and results in increased activity of CASP3 protein; Tretinoin promotes the reaction [pevonedistat results in increased cleavage of and results in increased activity of CASP3 protein]

PMID:22110742 PMID:34476871

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

C-C motif chemokine ligand 17

affects expression

pevonedistat affects the expression of CCL17 mRNA

NCBI chr19:10,202,128...10,203,903
Ensembl chr19:10,202,128...10,203,819

G

C-C motif chemokine ligand 22

affects expression

pevonedistat affects the expression of CCL22 mRNA

NCBI chr19:10,257,602...10,264,373
Ensembl chr19:10,257,601...10,264,400

G

C-C motif chemokine ligand 5

affects expression

pevonedistat affects the expression of CCL5 mRNA

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

cyclin D1

affects expression

pevonedistat affects the expression of CCND1 mRNA

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin D2

affects expression

pevonedistat affects the expression of CCND2 mRNA

NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495

G

CD40 molecule

affects expression

pevonedistat affects the expression of CD40 mRNA

NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534

G

CD74 molecule

affects expression

pevonedistat affects the expression of CD74 mRNA

NCBI chr18:54,256,757...54,266,003
Ensembl chr18:54,256,778...54,266,003

G

chromatin licensing and DNA replication factor 1

increases abundance

pevonedistat results in increased abundance of CDT1 protein

NCBI chr19:50,620,713...50,625,659
Ensembl chr19:50,620,713...50,625,659

G

CASP8 and FADD-like apoptosis regulator

affects expression

pevonedistat affects the expression of CFLAR mRNA

NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034

G

catenin beta 1

increases abundance
multiple interactions

pevonedistat results in increased abundance of CTNNB1 protein
pevonedistat inhibits the reaction [Cisplatin results in decreased expression of CTNNB1 mRNA]

PMID:22110742 PMID:34476871

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

cullin 1

decreases metabolic processing

pevonedistat results in decreased metabolism of CUL1 protein

NCBI chr 4:76,551,952...76,625,830
Ensembl chr 4:76,551,983...76,627,980

G

C-X-C motif chemokine ligand 9

affects expression

pevonedistat affects the expression of CXCL9 mRNA

NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435

G

C-X-C motif chemokine receptor 3

affects expression

pevonedistat affects the expression of CXCR3 mRNA

NCBI chr X:66,844,318...66,846,969
Ensembl chr X:66,844,318...66,846,969

G

C-X-C motif chemokine receptor 5

affects expression

pevonedistat affects the expression of CXCR5 mRNA

NCBI chr 8:44,842,098...44,858,425
Ensembl chr 8:44,843,413...44,857,893

G

endothelial PAS domain protein 1

multiple interactions

[Formaldehyde co-treated with pevonedistat co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the folding of EPAS1 protein

NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228

G

growth arrest and DNA-damage-inducible, beta

affects expression

pevonedistat affects the expression of GADD45B mRNA

NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046

G

hypoxia inducible factor 1 subunit alpha

multiple interactions

[Formaldehyde co-treated with pevonedistat co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the folding of HIF1A protein

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

heat shock transcription factor 1

increases activity

pevonedistat results in increased activity of HSF1 protein

NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011

G

interleukin 1 beta

multiple interactions

pevonedistat inhibits the reaction [Cisplatin results in increased expression of IL1B protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

pevonedistat inhibits the reaction [Cisplatin results in increased expression of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases abundance
multiple interactions

pevonedistat results in increased abundance of JUN protein
Tretinoin promotes the reaction [pevonedistat results in increased abundance of JUN protein]

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

MAF1 homolog, negative regulator of RNA polymerase III

increases expression

pevonedistat results in increased expression of MAF1 protein

NCBI chr 7:108,075,173...108,078,252
Ensembl chr 7:108,075,189...108,078,249

G

Mir155 host gene

affects expression

pevonedistat affects the expression of MIR155HG mRNA

NCBI chr11:23,773,468...23,775,697

G

MYC proto-oncogene, bHLH transcription factor

increases expression

pevonedistat results in increased expression of MYC protein

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

NFE2 like bZIP transcription factor 2

multiple interactions

pevonedistat inhibits the reaction [Cisplatin results in decreased expression of NFE2L2 mRNA]

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear factor kappa B subunit 1

affects activity

pevonedistat affects the activity of NFKB1 protein

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

NFKB inhibitor alpha

increases phosphorylation

pevonedistat results in increased phosphorylation of NFKBIA protein

PMID:22110742 PMID:24634471

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

poly (ADP-ribose) polymerase 1

increases cleavage
multiple interactions

pevonedistat results in increased cleavage of PARP1 protein
pevonedistat results in increased cleavage of and results in increased activity of PARP1 protein; Tretinoin promotes the reaction [pevonedistat results in increased cleavage of and results in increased activity of PARP1 protein]

PMID:22110742 PMID:24634471

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

phorbol-12-myristate-13-acetate-induced protein 1

increases abundance
affects expression
multiple interactions

pevonedistat results in increased abundance of PMAIP1 protein
pevonedistat affects the expression of PMAIP1 mRNA
Tretinoin promotes the reaction [pevonedistat results in increased abundance of PMAIP1 protein]

PMID:22110742 PMID:24634471

NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429

G

RELA proto-oncogene, NF-kB subunit

affects activity

pevonedistat affects the activity of RELA protein

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

RPTOR independent companion of MTOR, complex 2

increases expression

pevonedistat results in increased expression of RICTOR protein

NCBI chr 2:55,811,877...55,903,893
Ensembl chr 2:55,811,322...55,901,426

G

regulatory associated protein of MTOR, complex 1

increases expression

pevonedistat results in increased expression of RPTOR protein

NCBI chr10:104,878,487...105,176,986
Ensembl chr10:104,878,487...105,176,983

G

spalt-like transcription factor 4

multiple interactions

pevonedistat inhibits the reaction [Thalidomide results in increased degradation of and results in decreased expression of SALL4 protein]

NCBI chr 3:157,474,067...157,491,055
Ensembl chr 3:157,474,642...157,490,822

G

signal transducer and activator of transcription 5A

affects expression

pevonedistat affects the expression of STAT5A mRNA

NCBI chr10:85,785,537...85,809,869
Ensembl chr10:85,785,537...85,809,866

G

tumor necrosis factor

multiple interactions

pevonedistat inhibits the reaction [Cisplatin results in increased expression of TNF protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF alpha induced protein 3

multiple interactions

pevonedistat inhibits the reaction [Cisplatin results in decreased expression of TNFAIP3 mRNA]

NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282

G

ubiquitin-like modifier activating enzyme 3

decreases activity

pevonedistat results in decreased activity of UBA3 protein

NCBI chr 4:129,789,526...129,810,707
Ensembl chr 4:129,789,204...129,810,606

G

WEE1 G2 checkpoint kinase

increases abundance

pevonedistat results in increased abundance of WEE1 protein

NCBI chr 1:164,173,681...164,197,688
Ensembl chr 1:164,174,779...164,197,688

PF-956980

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

C-C motif chemokine ligand 2

multiple interactions

PF 956980 inhibits the reaction [OSM protein results in increased expression of CCL2 mRNA]

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

Janus kinase 3

multiple interactions

PF 956980 inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK3 protein]

NCBI chr16:18,386,330...18,398,542
Ensembl chr16:18,386,405...18,398,536

G

oncostatin M

multiple interactions

PF 956980 inhibits the reaction [OSM protein results in increased expression of CCL2 mRNA]; PF 956980 inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK3 protein]; PF 956980 inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of STAT1 protein]

NCBI chr14:79,103,638...79,108,500
Ensembl chr14:79,104,344...79,108,313

G

signal transducer and activator of transcription 1

multiple interactions

PF 956980 inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of STAT1 protein]

NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540

ruxolitinib

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

apoptotic peptidase activating factor 1

multiple interactions

[ruxolitinib co-treated with Arsenic Trioxide] results in increased expression of APAF1 mRNA

NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540

G

ATM serine/threonine kinase

multiple interactions

[ruxolitinib co-treated with Arsenic Trioxide] results in increased phosphorylation of ATM protein

NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437

G

BCL2 associated X, apoptosis regulator

multiple interactions

ruxolitinib inhibits the reaction [Carbon Tetrachloride results in increased expression of BAX protein]
[ruxolitinib co-treated with Arsenic Trioxide] results in increased expression of BAX mRNA

PMID:24973641 PMID:30012499

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

Bcl-2 binding component 3

multiple interactions

[ruxolitinib co-treated with Arsenic Trioxide] results in increased expression of BBC3 mRNA

NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509

G

BCL2, apoptosis regulator

multiple interactions

[ruxolitinib co-treated with Arsenic Trioxide] results in decreased expression of BCL2 mRNA

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

baculoviral IAP repeat-containing 5

multiple interactions

[ruxolitinib co-treated with Arsenic Trioxide] results in decreased expression of BIRC5 mRNA

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

catalase

multiple interactions

[ruxolitinib co-treated with Arsenic Trioxide] results in decreased expression of CAT mRNA

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cyclin D1

multiple interactions

[ruxolitinib co-treated with Arsenic Trioxide] results in decreased expression of CCND1 mRNA

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cadherin 1

multiple interactions

ruxolitinib inhibits the reaction [DDT results in decreased expression of CDH1 mRNA]

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

cadherin 2

multiple interactions

ruxolitinib inhibits the reaction [DDT results in increased expression of CDH2 mRNA]

NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167

G

cyclin dependent kinase 2

multiple interactions

[ruxolitinib co-treated with Arsenic Trioxide] results in decreased expression of CDK2 mRNA

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

checkpoint kinase 2

multiple interactions

[ruxolitinib co-treated with Arsenic Trioxide] results in increased phosphorylation of CHEK2 protein

NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286

G

C-X-C motif chemokine ligand 10

multiple interactions
decreases expression

ruxolitinib inhibits the reaction [IFNB1 protein results in increased expression of CXCL10 mRNA]; ruxolitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 mRNA]
ruxolitinib results in decreased expression of CXCL10 mRNA

PMID:22941906 PMID:28365849

NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975

G

C-X-C motif chemokine ligand 11

multiple interactions
decreases expression

ruxolitinib inhibits the reaction [IFNB1 protein results in increased expression of CXCL11 mRNA]; ruxolitinib inhibits the reaction [TNF protein results in increased expression of CXCL11 mRNA]
ruxolitinib results in decreased expression of CXCL11 mRNA

PMID:22941906 PMID:28365849

NCBI chr14:15,689,432...15,692,207
Ensembl chr14:15,689,424...15,692,271

G

endothelin 1

decreases phosphorylation

ruxolitinib results in decreased phosphorylation of EDN1 protein

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

glutamic--pyruvic transaminase

multiple interactions

ruxolitinib inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione-disulfide reductase

multiple interactions

[ruxolitinib co-treated with Arsenic Trioxide] results in decreased expression of GSR mRNA

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

H2A.X variant histone

multiple interactions

[Arsenic Trioxide co-treated with ruxolitinib] results in increased phosphorylation of H2AX protein

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
Ensembl chr 4:44,671,786...44,673,239

G

interferon, alpha 1

multiple interactions

ruxolitinib inhibits the reaction [IFNA1 protein affects the localization of and results in increased phosphorylation of STAT1 protein]; ruxolitinib inhibits the reaction [IFNA1 protein affects the localization of and results in increased phosphorylation of STAT2 protein]

NCBI chr 5:103,097,356...103,097,925
Ensembl chr 5:103,097,356...103,097,925

G

interferon beta 1

multiple interactions

ruxolitinib inhibits the reaction [IFNB1 protein results in increased expression of CXCL10 mRNA]; ruxolitinib inhibits the reaction [IFNB1 protein results in increased expression of CXCL11 mRNA]; ruxolitinib inhibits the reaction [IFNB1 protein results in increased expression of IRF1 mRNA]; ruxolitinib inhibits the reaction [IFNB1 protein results in increased expression of IRF9 mRNA]; ruxolitinib inhibits the reaction [IFNB1 protein results in increased expression of SP100 mRNA]; ruxolitinib inhibits the reaction [IFNB1 protein results in increased expression of STAT1 mRNA]; ruxolitinib inhibits the reaction [IFNB1 protein results in increased expression of STAT2 mRNA]; ruxolitinib inhibits the reaction [IFNB1 protein results in increased expression of TLR3 mRNA]

NCBI chr 5:103,020,758...103,021,595
Ensembl chr 5:103,020,969...103,021,523

G

interferon gamma

multiple interactions

ruxolitinib inhibits the reaction [IFNG protein affects the localization of and results in increased phosphorylation of STAT1 protein]; ruxolitinib inhibits the reaction [IFNG protein affects the localization of and results in increased phosphorylation of STAT2 protein]

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 10

multiple interactions

ruxolitinib inhibits the reaction [Carbon Tetrachloride results in increased secretion of IL10 protein]

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 13

multiple interactions

ruxolitinib inhibits the reaction [Particulate Matter results in increased secretion of IL13 protein]

NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737

G

interleukin 17A

multiple interactions

ruxolitinib inhibits the reaction [Carbon Tetrachloride results in increased secretion of and results in decreased expression of IL17A protein]

NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889

G

interleukin 1 beta

multiple interactions

ruxolitinib inhibits the reaction [Carbon Tetrachloride results in increased secretion of IL1B protein]
ruxolitinib inhibits the reaction [Particulate Matter results in increased secretion of IL1B protein]

PMID:24973641 PMID:32725971

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 5

multiple interactions

ruxolitinib inhibits the reaction [Particulate Matter results in increased secretion of IL5 protein]

NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213

G

interferon regulatory factor 1

multiple interactions

ruxolitinib inhibits the reaction [IFNB1 protein results in increased expression of IRF1 mRNA]

NCBI chr10:37,917,155...37,924,166
Ensembl chr10:37,916,670...37,924,166

G

interferon regulatory factor 7

decreases expression

ruxolitinib results in decreased expression of IRF7 mRNA

NCBI chr 1:196,367,380...196,370,943
Ensembl chr 1:196,367,361...196,370,832

G

interferon regulatory factor 9

multiple interactions

ruxolitinib inhibits the reaction [IFNB1 protein results in increased expression of IRF9 mRNA]

NCBI chr15:29,095,474...29,101,924
Ensembl chr15:29,095,789...29,101,236

G

integrin subunit beta 1

multiple interactions

ruxolitinib inhibits the reaction [DDT results in increased expression of ITGB1 mRNA]

NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195

G

Janus kinase 1

multiple interactions
decreases activity

ruxolitinib inhibits the reaction [DDT results in increased phosphorylation of JAK1 protein]
ruxolitinib results in decreased activity of JAK1 protein

PMID:24820114 PMID:24883332 PMID:26300391

NCBI chr 5:115,780,248...115,888,841
Ensembl chr 5:115,780,248...115,888,926

G

Janus kinase 2

affects response to substance
multiple interactions
decreases activity

JAK2 gene mutant form affects the susceptibility to ruxolitinib
[ruxolitinib co-treated with Arsenic Trioxide] results in decreased phosphorylation of JAK2 protein
ruxolitinib results in decreased activity of JAK2 protein

PMID:24883332 PMID:26300391 PMID:30012499

NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

ruxolitinib promotes the reaction [TNF protein affects the localization of JUN protein]

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

myeloperoxidase

multiple interactions

ruxolitinib inhibits the reaction [Carbon Tetrachloride results in increased activity of MPO protein]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions

[ruxolitinib co-treated with Arsenic Trioxide] results in decreased expression of MYC mRNA

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

nuclear factor of activated T-cells 1

multiple interactions

ruxolitinib promotes the reaction [TNF protein affects the localization of NFATC1 protein]

NCBI chr18:74,046,422...74,156,041
Ensembl chr18:74,046,904...74,156,028

G

nuclear factor kappa B subunit 2

multiple interactions

ruxolitinib inhibits the reaction [TNF protein affects the localization of NFKB2 protein]

NCBI chr 1:245,164,586...245,173,225
Ensembl chr 1:245,165,950...245,173,213

G

NADPH oxidase 1

multiple interactions

[ruxolitinib co-treated with Arsenic Trioxide] results in increased expression of NOX1 mRNA

NCBI chr X:97,279,058...97,332,291
Ensembl chr X:97,279,056...97,302,236

G

Rac family small GTPase 1

multiple interactions

[ruxolitinib co-treated with Arsenic Trioxide] results in increased expression of RAC1 mRNA

NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

ruxolitinib inhibits the reaction [Carbon Tetrachloride results in increased expression of and affects the localization of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

RELB proto-oncogene, NF-kB subunit

multiple interactions

ruxolitinib inhibits the reaction [TNF protein affects the localization of RELB protein]

NCBI chr 1:79,257,738...79,285,490
Ensembl chr 1:79,257,725...79,285,507

G

superoxide dismutase 1

multiple interactions

[ruxolitinib co-treated with Arsenic Trioxide] results in decreased expression of SOD1 mRNA

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

SP100 nuclear antigen

multiple interactions

ruxolitinib inhibits the reaction [IFNB1 protein results in increased expression of SP100 mRNA]

NCBI chr 9:86,310,990...86,377,036
Ensembl chr 9:86,311,032...86,377,034

G

signal transducer and activator of transcription 1

decreases expression
decreases phosphorylation
multiple interactions

ruxolitinib results in decreased expression of STAT1 mRNA
ruxolitinib results in decreased phosphorylation of STAT1 protein
ruxolitinib inhibits the reaction [IFNA1 protein affects the localization of and results in increased phosphorylation of STAT1 protein]; ruxolitinib inhibits the reaction [IFNB1 protein results in increased expression of STAT1 mRNA]; ruxolitinib inhibits the reaction [IFNG protein affects the localization of and results in increased phosphorylation of STAT1 protein]; ruxolitinib inhibits the reaction [TNF protein affects the localization of and results in increased phosphorylation of STAT1 protein]

PMID:22941906 PMID:28365849

NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540

G

signal transducer and activator of transcription 2

multiple interactions

ruxolitinib inhibits the reaction [IFNA1 protein affects the localization of and results in increased phosphorylation of STAT2 protein]; ruxolitinib inhibits the reaction [IFNB1 protein results in increased expression of STAT2 mRNA]; ruxolitinib inhibits the reaction [IFNG protein affects the localization of and results in increased phosphorylation of STAT2 protein]

PMID:22941906 PMID:28365849

NCBI chr 7:702,565...718,349
Ensembl chr 7:702,495...718,967

G

signal transducer and activator of transcription 3

multiple interactions

[ruxolitinib co-treated with Arsenic Trioxide] results in decreased phosphorylation of STAT3 protein; ruxolitinib inhibits the reaction [DDT results in increased phosphorylation of STAT3 protein]

PMID:24820114 PMID:30012499

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

signal transducer and activator of transcription 5B

decreases phosphorylation

ruxolitinib results in decreased phosphorylation of STAT5B protein
ruxolitinib results in decreased phosphorylation of STAT5B protein; ruxolitinib results in decreased phosphorylation of STAT5B protein mutant form

NCBI chr10:85,704,841...85,775,856
Ensembl chr10:85,705,670...85,775,668

G

toll-like receptor 3

multiple interactions

ruxolitinib inhibits the reaction [IFNB1 protein results in increased expression of TLR3 mRNA]

NCBI chr16:46,821,980...46,837,900
Ensembl chr16:46,822,039...46,836,545

G

tumor necrosis factor

multiple interactions

ruxolitinib inhibits the reaction [TNF protein affects the localization of and results in increased phosphorylation of STAT1 protein]; ruxolitinib inhibits the reaction [TNF protein affects the localization of NFKB2 protein]; ruxolitinib inhibits the reaction [TNF protein affects the localization of RELB protein]; ruxolitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 mRNA]; ruxolitinib inhibits the reaction [TNF protein results in increased expression of CXCL11 mRNA]; ruxolitinib inhibits the reaction [TNF protein results in increased expression of IFIT1 mRNA]; ruxolitinib promotes the reaction [TNF protein affects the localization of JUN protein]; ruxolitinib promotes the reaction [TNF protein affects the localization of NFATC1 protein]
ruxolitinib inhibits the reaction [Carbon Tetrachloride results in increased expression of and results in increased secretion of TNF protein]

PMID:22941906 PMID:24973641

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

multiple interactions

[ruxolitinib co-treated with Arsenic Trioxide] results in increased expression of TP53 mRNA; [ruxolitinib co-treated with Arsenic Trioxide] results in increased expression of TP53 protein

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

thioredoxin reductase 1

multiple interactions

[ruxolitinib co-treated with Arsenic Trioxide] results in decreased expression of TXNRD1 mRNA

NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863

G

uncoupling protein 1

increases expression

ruxolitinib results in increased expression of UCP1 mRNA

NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852

G

vascular endothelial growth factor A

increases expression

ruxolitinib results in increased expression of VEGFA mRNA

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

tofacitinib

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aryl hydrocarbon receptor

multiple interactions

tofacitinib inhibits the reaction [[IL6 protein co-treated with TGFB1 protein] results in increased expression of AHR mRNA]

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

aldo-keto reductase family 1, member C1

increases metabolic processing

AKR1C1 protein results in increased metabolism of tofacitinib metabolite

NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326

G

AKT serine/threonine kinase 1

multiple interactions

tofacitinib inhibits the reaction [IL2 protein results in increased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

adenosine monophosphate deaminase 2

multiple interactions
decreases expression

[tofacitinib results in decreased expression of AMPD2 protein] which affects the abundance of Adenosine

NCBI chr 2:195,707,609...195,720,454
Ensembl chr 2:195,707,610...195,720,271

G

bone marrow stromal cell antigen 2

decreases expression

tofacitinib results in decreased expression of BST2 mRNA

NCBI chr16:18,216,605...18,220,979
Ensembl chr16:18,217,407...18,220,979

G

C-C motif chemokine ligand 2

decreases expression
multiple interactions

tofacitinib results in decreased expression of CCL2 mRNA
Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL2 protein]]; tofacitinib inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CCL2 protein]; tofacitinib inhibits the reaction [OSM protein results in increased expression of CCL2 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL2 protein]

PMID:22121136 PMID:23968543 PMID:25398374 PMID:36416909

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 3

multiple interactions

tofacitinib inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CCL3 protein]

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

C-C motif chemokine ligand 5

multiple interactions

Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL5 protein]]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL5 protein]

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

cyclin D1

increases expression

tofacitinib results in increased expression of CCND1 mRNA

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cathepsin K

decreases expression

tofacitinib results in decreased expression of CTSK protein

NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550

G

C-X-C motif chemokine ligand 10

decreases expression
multiple interactions
decreases secretion

tofacitinib results in decreased expression of CXCL10 mRNA
Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 protein]]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 protein]
tofacitinib inhibits the reaction [IFNG protein results in increased expression of CXCL10 mRNA]
tofacitinib results in decreased secretion of CXCL10 protein

PMID:22121136 PMID:22899318 PMID:22941906 PMID:24213371 PMID:25398374 More...

NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975

G

C-X-C motif chemokine ligand 11

decreases expression
multiple interactions

tofacitinib results in decreased expression of CXCL11 mRNA
tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL11 mRNA]

NCBI chr14:15,689,432...15,692,207
Ensembl chr14:15,689,424...15,692,271

G

C-X-C motif chemokine ligand 13

decreases expression

tofacitinib results in decreased expression of CXCL13 mRNA

NCBI chr14:13,608,894...13,613,965
Ensembl chr14:13,608,902...13,613,933

G

C-X-C motif chemokine ligand 9

multiple interactions
decreases expression

tofacitinib inhibits the reaction [IFNG protein results in increased expression of CXCL9 mRNA]
tofacitinib results in decreased expression of CXCL9 mRNA

PMID:22941906 PMID:24213371

NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435

G

cytochrome P450, family 1, subfamily a, polypeptide 2

increases metabolic processing

CYP1A2 protein results in increased metabolism of tofacitinib

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 2, subfamily C, polypeptide 6

increases metabolic processing

CYP2C19 protein results in increased metabolism of tofacitinib

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 2, subfamily d, polypeptide 4

increases metabolic processing

CYP2D6 protein results in increased metabolism of tofacitinib

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases metabolic processing
increases oxidation

CYP3A4 protein results in increased metabolism of tofacitinib
CYP3A4 protein results in increased oxidation of tofacitinib metabolite

PMID:27117606 PMID:31414593

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

GLI family zinc finger 1

increases expression

tofacitinib results in increased expression of GLI1 mRNA

NCBI chr 7:63,156,926...63,169,579
Ensembl chr 7:63,156,926...63,169,251

G

interferon, alpha-inducible protein 27

decreases expression

tofacitinib results in decreased expression of IFI27 mRNA

NCBI chr 6:122,590,461...122,596,996
Ensembl chr 6:122,590,472...122,779,294

G

interferon-induced protein 35

decreases expression

tofacitinib results in decreased expression of IFI35 mRNA

NCBI chr10:86,381,023...86,389,279
Ensembl chr10:86,381,010...86,389,952

G

interferon-induced protein 44

decreases expression

tofacitinib results in decreased expression of IFI44 mRNA

NCBI chr 2:240,626,058...240,643,879
Ensembl chr 2:240,626,066...240,643,844

G

interferon-induced protein with tetratricopeptide repeats 3

decreases expression

tofacitinib results in decreased expression of IFIT3 mRNA

NCBI chr 1:232,114,166...232,119,311
Ensembl chr 1:232,114,166...232,119,307

G

interferon induced transmembrane protein 1

decreases expression

tofacitinib results in decreased expression of IFITM1 mRNA

NCBI chr 1:196,067,163...196,069,169
Ensembl chr 1:196,067,963...196,069,169

G

interferon, alpha 1

multiple interactions

tofacitinib inhibits the reaction [IFNA1 protein affects the localization of and results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [IFNA1 protein affects the localization of and results in increased phosphorylation of STAT2 protein]

NCBI chr 5:103,097,356...103,097,925
Ensembl chr 5:103,097,356...103,097,925

G

interferon gamma

multiple interactions

tofacitinib inhibits the reaction [IFNG protein results in increased expression of CXCL10 mRNA]; tofacitinib inhibits the reaction [IFNG protein results in increased expression of CXCL9 mRNA]; tofacitinib inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IFNG protein]
tofacitinib affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IFNG protein] results in increased secretion of TNF protein]; tofacitinib inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IFNG protein] results in increased secretion of CXCL8 protein]; tofacitinib inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IFNG protein] results in increased secretion of IL1B protein]; tofacitinib inhibits the reaction [IFNG protein affects the localization of and results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [IFNG protein affects the localization of and results in increased phosphorylation of STAT2 protein]

PMID:21383241 PMID:22941906 PMID:24213371 PMID:33130239

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 10

multiple interactions

tofacitinib inhibits the reaction [IL6 protein results in increased expression of IL10 mRNA]; tofacitinib inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL10 protein]

PMID:21383241 PMID:24285838

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 12B

multiple interactions

tofacitinib inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL12B protein]

NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903

G

interleukin 15

multiple interactions

tofacitinib inhibits the reaction [IL15 protein results in increased phosphorylation of STAT5A protein]; tofacitinib inhibits the reaction [IL15 protein results in increased phosphorylation of STAT5B protein]

NCBI chr19:25,640,025...25,706,818
Ensembl chr19:25,640,251...25,706,820

G

interleukin 17A

multiple interactions

tofacitinib inhibits the reaction [enterotoxin A, Staphylococcal results in increased expression of and results in increased secretion of IL17A protein]

NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889

G

interleukin 1 beta

multiple interactions
decreases expression

tofacitinib inhibits the reaction [IL1B protein results in increased expression of IL6 mRNA]; tofacitinib inhibits the reaction [IL1B protein results in increased expression of IL6 protein]; tofacitinib inhibits the reaction [IL1B protein results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL1B protein]
tofacitinib inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IFNG protein] results in increased secretion of IL1B protein]; tofacitinib inhibits the reaction [TNF protein affects the expression of IL1B mRNA]
tofacitinib results in decreased expression of IL1B mRNA

PMID:21383241 PMID:21937456 PMID:22899318 PMID:22941906 PMID:33130239

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 2

multiple interactions

tofacitinib inhibits the reaction [IL2 protein results in increased phosphorylation of AKT1 protein]; tofacitinib inhibits the reaction [IL2 protein results in increased phosphorylation of STAT5A protein]; tofacitinib inhibits the reaction [IL2 protein results in increased phosphorylation of STAT5B protein]

PMID:21155605 PMID:21383241

NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566

G

interleukin 21

multiple interactions

tofacitinib inhibits the reaction [IL21 protein results in increased phosphorylation of STAT3 protein]
tofacitinib inhibits the reaction [IL21 protein results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [IL21 protein results in increased phosphorylation of STAT3 protein]

NCBI chr 2:120,117,105...120,127,012
Ensembl chr 2:120,119,444...120,126,996

G

interleukin 23 subunit alpha

multiple interactions

tofacitinib inhibits the reaction [[IL6 protein co-treated with IL23A protein] results in increased expression of IL23R mRNA]; tofacitinib inhibits the reaction [[IL6 protein co-treated with IL23A protein] results in increased expression of RORC mRNA]; tofacitinib inhibits the reaction [IL23A protein results in increased phosphorylation of STAT3 protein]

PMID:21383241 PMID:21937456

NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923

G

interleukin 23 receptor

multiple interactions

tofacitinib inhibits the reaction [[IL6 protein co-treated with IL23A protein] results in increased expression of IL23R mRNA]

NCBI chr 4:96,580,568...96,672,540
Ensembl chr 4:96,580,714...96,674,021

G

interleukin 4

multiple interactions

tofacitinib inhibits the reaction [IL4 protein results in increased phosphorylation of STAT6 protein]

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

interleukin 6

decreases expression
multiple interactions

tofacitinib results in decreased expression of IL6 mRNA
tofacitinib inhibits the reaction [[IL6 protein co-treated with IL6R protein] results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [IL6 protein results in increased expression of SAA1 mRNA]; tofacitinib inhibits the reaction [IL6 protein results in increased expression of SAA2 mRNA]; tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of JAK2 protein]; tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [Mustard Gas results in increased secretion of IL6 protein]; tofacitinib inhibits the reaction [OSM protein results in increased expression of and results in increased secretion of IL6 protein]; tofacitinib inhibits the reaction [OSM protein results in increased expression of IL6 mRNA]
tofacitinib results in decreased expression of and results in decreased secretion of IL6 protein
tofacitinib inhibits the reaction [[IL6 protein co-treated with IL23A protein] results in increased expression of IL23R mRNA]; tofacitinib inhibits the reaction [[IL6 protein co-treated with IL23A protein] results in increased expression of RORC mRNA]; tofacitinib inhibits the reaction [[IL6 protein co-treated with TGFB1 protein] results in increased expression of AHR mRNA]; tofacitinib inhibits the reaction [[IL6 protein co-treated with TGFB1 protein] results in increased expression of RORC mRNA]; tofacitinib inhibits the reaction [IL1B protein results in increased expression of IL6 mRNA]; tofacitinib inhibits the reaction [IL1B protein results in increased expression of IL6 protein]; tofacitinib inhibits the reaction [IL6 protein results in increased expression of IL10 mRNA]; tofacitinib inhibits the reaction [IL6 protein results in increased expression of IL6 mRNA]; tofacitinib inhibits the reaction [IL6 protein results in increased expression of TNFSF11 mRNA]; tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL6 protein]; tofacitinib inhibits the reaction [OSM protein results in increased expression of IL6 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of IL6 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of IL6 protein]; tofacitinib promotes the reaction [IL6 protein results in increased expression of MMP9 mRNA]

PMID:21383241 PMID:21548952 PMID:21844139 PMID:21937456 PMID:22121136 More...

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

interleukin 6 receptor

multiple interactions

tofacitinib inhibits the reaction [[IL6 protein co-treated with IL6R protein] results in increased phosphorylation of STAT3 protein]

NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536

G

interferon regulatory factor 7

decreases expression

tofacitinib results in decreased expression of IRF7 mRNA

PMID:22941906 PMID:25487280

NCBI chr 1:196,367,380...196,370,943
Ensembl chr 1:196,367,361...196,370,832

G

interferon regulatory factor 9

decreases expression

tofacitinib results in decreased expression of IRF9 mRNA

NCBI chr15:29,095,474...29,101,924
Ensembl chr15:29,095,789...29,101,236

G

ISG15 ubiquitin-like modifier

decreases expression

tofacitinib results in decreased expression of ISG15 mRNA

NCBI chr 5:166,784,148...166,785,435
Ensembl chr 5:166,784,148...166,785,435

G

Janus kinase 1

decreases activity
multiple interactions

tofacitinib results in decreased activity of JAK1 protein
tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK1 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of JAK1 protein]

PMID:21548952 PMID:23968543 PMID:24883332

NCBI chr 5:115,780,248...115,888,841
Ensembl chr 5:115,780,248...115,888,926

G

Janus kinase 2

affects response to substance
multiple interactions
decreases activity

JAK2 gene mutant form affects the susceptibility to tofacitinib
tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of JAK2 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK2 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of JAK2 protein]
tofacitinib results in decreased activity of JAK2 protein

PMID:21548952 PMID:21844139 PMID:23968543 PMID:26300391

NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189

G

Janus kinase 3

decreases activity
multiple interactions

tofacitinib results in decreased activity of JAK3 protein
tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK3 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of JAK3 protein]

PMID:21548952 PMID:23689514 PMID:23968543 PMID:24883332 PMID:26300391 More...

NCBI chr16:18,386,330...18,398,542
Ensembl chr16:18,386,405...18,398,536

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

tofacitinib promotes the reaction [TNF protein affects the localization of JUN protein]

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

kelch-like family member 31

increases expression

tofacitinib results in increased expression of KLHL31 mRNA

NCBI chr 8:78,515,514...78,538,873
Ensembl chr 8:78,515,514...78,538,873

G

keratin 16

decreases expression

tofacitinib results in decreased expression of KRT16 mRNA

NCBI chr10:85,168,357...85,171,816
Ensembl chr10:85,066,802...85,171,799

G

luteinizing hormone/choriogonadotropin receptor

multiple interactions

tofacitinib inhibits the reaction [PRL protein results in increased expression of LHCGR mRNA]

NCBI chr 6:5,661,871...5,728,109
Ensembl chr 6:5,661,871...5,724,521

G

mitogen activated protein kinase 1

multiple interactions

tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 8

multiple interactions

tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of MAPK8 protein]

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

mitogen-activated protein kinase 9

multiple interactions

tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of MAPK9 protein]

NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178

G

matrix metallopeptidase 1

decreases expression

tofacitinib results in decreased expression of MMP1 mRNA

NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097

G

matrix metallopeptidase 3

decreases expression

tofacitinib results in decreased expression of MMP3 mRNA

NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961

G

matrix metallopeptidase 9

multiple interactions

tofacitinib promotes the reaction [IL6 protein results in increased expression of MMP9 mRNA]

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

mitochondrially encoded cytochrome c oxidase I

increases expression

tofacitinib results in increased expression of COX1 protein

NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867

G

MX dynamin like GTPase 1

decreases expression

tofacitinib results in decreased expression of MX1 mRNA

NCBI chr11:36,799,659...36,825,209
Ensembl chr11:36,799,660...36,823,507

G

MX dynamin like GTPase 2

decreases expression

tofacitinib results in decreased expression of MX2 mRNA

NCBI chr11:36,905,698...36,936,308
Ensembl chr11:36,906,111...36,930,342

G

nuclear factor of activated T-cells 1

multiple interactions

tofacitinib promotes the reaction [TNF protein affects the localization of NFATC1 protein]

NCBI chr18:74,046,422...74,156,041
Ensembl chr18:74,046,904...74,156,028

G

nuclear factor kappa B subunit 2

multiple interactions

tofacitinib inhibits the reaction [TNF protein affects the localization of NFKB2 protein]

NCBI chr 1:245,164,586...245,173,225
Ensembl chr 1:245,165,950...245,173,213

G

2'-5' oligoadenylate synthetase 1A

decreases expression

tofacitinib results in decreased expression of OAS1 mRNA

NCBI chr12:35,669,798...35,680,505
Ensembl chr12:35,669,801...35,680,517

G

2'-5' oligoadenylate synthetase 2

decreases expression

tofacitinib results in decreased expression of OAS2 mRNA

NCBI chr12:35,802,824...35,830,778
Ensembl chr12:35,806,759...35,829,371

G

oncostatin M

multiple interactions

tofacitinib inhibits the reaction [OSM protein results in increased expression of IL6 mRNA]; tofacitinib inhibits the reaction [OSM protein results in increased expression of TNFSF11 mRNA]
tofacitinib inhibits the reaction [OSM protein results in increased expression of and results in increased secretion of IL6 protein]; tofacitinib inhibits the reaction [OSM protein results in increased expression of CCL2 mRNA]; tofacitinib inhibits the reaction [OSM protein results in increased expression of IL6 mRNA]; tofacitinib inhibits the reaction [OSM protein results in increased expression of S100A7 protein]; tofacitinib inhibits the reaction [OSM protein results in increased expression of SAA1 mRNA]; tofacitinib inhibits the reaction [OSM protein results in increased expression of SAA2 mRNA]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK1 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK2 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of JAK3 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of STAT1 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of STAT3 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of JAK1 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of JAK2 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of JAK3 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of MAPK1 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of MAPK3 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of MAPK8 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of MAPK9 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of STAT3 protein]

PMID:21548952 PMID:21937456 PMID:23968543 PMID:25252914

NCBI chr14:79,103,638...79,108,500
Ensembl chr14:79,104,344...79,108,313

G

PR/SET domain 16

increases expression

tofacitinib results in increased expression of PRDM16 protein

NCBI chr 5:164,879,864...165,203,986
Ensembl chr 5:164,880,587...165,203,601

G

prolactin

multiple interactions

tofacitinib inhibits the reaction [PRL protein results in increased expression of LHCGR mRNA]; tofacitinib inhibits the reaction [PRL protein results in increased phosphorylation of STAT5A protein]; tofacitinib inhibits the reaction [PRL protein results in increased phosphorylation of STAT5B protein]

NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062

G

RELB proto-oncogene, NF-kB subunit

multiple interactions

tofacitinib inhibits the reaction [TNF protein affects the localization of RELB protein]

NCBI chr 1:79,257,738...79,285,490
Ensembl chr 1:79,257,725...79,285,507

G

RAR-related orphan receptor C

multiple interactions

tofacitinib inhibits the reaction [[IL6 protein co-treated with IL23A protein] results in increased expression of RORC mRNA]; tofacitinib inhibits the reaction [[IL6 protein co-treated with TGFB1 protein] results in increased expression of RORC mRNA]

NCBI chr 2:182,009,707...182,034,910
Ensembl chr 2:182,009,286...182,034,907

G

radical S-adenosyl methionine domain containing 2

decreases expression

tofacitinib results in decreased expression of RSAD2 mRNA

NCBI chr 6:43,046,514...43,059,737
Ensembl chr 6:43,047,658...43,059,699

G

succinate dehydrogenase complex flavoprotein subunit A

increases expression

tofacitinib results in increased expression of SDHA protein

NCBI chr 1:28,935,965...28,960,936
Ensembl chr 1:28,940,164...28,961,535

G

selectin E

decreases expression

tofacitinib results in decreased expression of SELE mRNA

NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741

G

selectin P

decreases expression

tofacitinib results in decreased expression of SELP mRNA

NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845

G

secreted frizzled-related protein 5

increases expression

tofacitinib results in increased expression of SFRP5 mRNA

NCBI chr 1:241,006,762...241,011,224
Ensembl chr 1:241,006,762...241,011,224

G

sonic hedgehog signaling molecule

increases expression

tofacitinib results in increased expression of SHH mRNA

NCBI chr 4:6,954,017...6,963,170
Ensembl chr 4:6,954,017...6,963,170

G

suppressor of cytokine signaling 3

decreases expression

tofacitinib results in decreased expression of SOCS3 mRNA

NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787

G

signal transducer and activator of transcription 1

decreases expression
multiple interactions
decreases phosphorylation

tofacitinib results in decreased expression of STAT1 mRNA; tofacitinib results in decreased expression of STAT1 protein modified form
tofacitinib inhibits the reaction [IFNA1 protein affects the localization of and results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [IFNG protein affects the localization of and results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of STAT1 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [TNF protein affects the localization of and results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [TNF protein results in increased phosphorylation of STAT1 protein]
tofacitinib inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [IL21 protein results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of STAT1 protein]
tofacitinib results in decreased phosphorylation of STAT1 protein

PMID:21383241 PMID:21548952 PMID:22121136 PMID:22941906 PMID:23968543 More...

NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540

G

signal transducer and activator of transcription 2

multiple interactions

tofacitinib inhibits the reaction [IFNA1 protein affects the localization of and results in increased phosphorylation of STAT2 protein]; tofacitinib inhibits the reaction [IFNG protein affects the localization of and results in increased phosphorylation of STAT2 protein]

NCBI chr 7:702,565...718,349
Ensembl chr 7:702,495...718,967

G

signal transducer and activator of transcription 3

decreases activity
multiple interactions
decreases expression
decreases phosphorylation

tofacitinib results in decreased activity of STAT3 protein
tofacitinib inhibits the reaction [[IL6 protein co-treated with IL6R protein] results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [IL21 protein results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of and results in increased activity of STAT3 protein]; tofacitinib inhibits the reaction [OSM protein results in increased phosphorylation of STAT3 protein]
tofacitinib inhibits the reaction [IL1B protein results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [IL21 protein results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [IL23A protein results in increased phosphorylation of STAT3 protein]; tofacitinib inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein]
tofacitinib results in decreased expression of STAT3 protein modified form
tofacitinib results in decreased phosphorylation of STAT3 protein

PMID:21383241 PMID:21548952 PMID:21844139 PMID:21937456 PMID:22121136 More...

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

signal transducer and activator of transcription 5A

decreases phosphorylation
multiple interactions

tofacitinib results in decreased phosphorylation of STAT5A protein
tofacitinib inhibits the reaction [PRL protein results in increased phosphorylation of STAT5A protein]
tofacitinib inhibits the reaction [IL2 protein results in increased phosphorylation of STAT5A protein]
tofacitinib inhibits the reaction [IL15 protein results in increased phosphorylation of STAT5A protein]

PMID:21155605 PMID:22705984 PMID:26244872 PMID:27708194

NCBI chr10:85,785,537...85,809,869
Ensembl chr10:85,785,537...85,809,866

G

signal transducer and activator of transcription 5B

decreases phosphorylation
multiple interactions

tofacitinib results in decreased phosphorylation of STAT5B protein; tofacitinib results in decreased phosphorylation of STAT5B protein mutant form
tofacitinib inhibits the reaction [IL2 protein results in increased phosphorylation of STAT5B protein]
tofacitinib inhibits the reaction [PRL protein results in increased phosphorylation of STAT5B protein]
tofacitinib inhibits the reaction [IL15 protein results in increased phosphorylation of STAT5B protein]

PMID:21155605 PMID:22705984 PMID:26244872 PMID:27708194 PMID:29200404

NCBI chr10:85,704,841...85,775,856
Ensembl chr10:85,705,670...85,775,668

G

signal transducer and activator of transcription 6

multiple interactions

tofacitinib inhibits the reaction [IL4 protein results in increased phosphorylation of STAT6 protein]

NCBI chr 7:63,480,229...63,497,551
Ensembl chr 7:63,479,642...63,498,495

G

transforming growth factor, beta 1

multiple interactions

tofacitinib inhibits the reaction [[IL6 protein co-treated with TGFB1 protein] results in increased expression of AHR mRNA]; tofacitinib inhibits the reaction [[IL6 protein co-treated with TGFB1 protein] results in increased expression of RORC mRNA]

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

tumor necrosis factor

multiple interactions

Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL2 protein]]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL5 protein]]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 protein]]; tofacitinib affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IFNG protein] results in increased secretion of TNF protein]; tofacitinib inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of TNF protein]; tofacitinib inhibits the reaction [TNF protein affects the expression of IL1B mRNA]; tofacitinib inhibits the reaction [TNF protein affects the localization of and results in increased phosphorylation of STAT1 protein]; tofacitinib inhibits the reaction [TNF protein affects the localization of NFKB2 protein]; tofacitinib inhibits the reaction [TNF protein affects the localization of RELB protein]; tofacitinib inhibits the reaction [TNF protein results in decreased expression of UCP1 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL2 protein]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL5 protein]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 protein]; tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL11 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of IFIT1 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased phosphorylation of STAT1 protein]; tofacitinib promotes the reaction [TNF protein affects the localization of JUN protein]; tofacitinib promotes the reaction [TNF protein affects the localization of NFATC1 protein]
tofacitinib inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of TNF protein]; tofacitinib inhibits the reaction [TNF protein results in increased expression of IL6 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of IL6 protein]; tofacitinib inhibits the reaction [TNF protein results in increased expression of TNFSF11 mRNA]

PMID:21383241 PMID:21937456 PMID:22121136 PMID:22941906 PMID:25487280 More...

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF superfamily member 10

decreases expression

tofacitinib results in decreased expression of TNFSF10 mRNA

NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135

G

TNF superfamily member 11

multiple interactions
decreases expression

tofacitinib results in decreased expression of and results in decreased secretion of TNFSF11 protein
tofacitinib results in decreased expression of TNFSF11 protein
tofacitinib results in decreased expression of TNFSF11 mRNA
tofacitinib inhibits the reaction [IL6 protein results in increased expression of TNFSF11 mRNA]; tofacitinib inhibits the reaction [OSM protein results in increased expression of TNFSF11 mRNA]; tofacitinib inhibits the reaction [TNF protein results in increased expression of TNFSF11 mRNA]

PMID:21937456 PMID:22899318

NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445

G

uncoupling protein 1

increases expression
multiple interactions

tofacitinib results in increased expression of UCP1 mRNA; tofacitinib results in increased expression of UCP1 protein
cyclopamine inhibits the reaction [tofacitinib results in increased expression of UCP1 mRNA]; tofacitinib inhibits the reaction [TNF protein results in decreased expression of UCP1 mRNA]

NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852

G

ubiquitin specific peptidase 18

decreases expression

tofacitinib results in decreased expression of USP18 mRNA

NCBI chr 4:154,471,634...154,499,154
Ensembl chr 4:154,471,592...154,499,144

G

vascular endothelial growth factor A

increases expression

tofacitinib results in increased expression of VEGFA mRNA

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

toyocamycin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

caspase 1

multiple interactions

Toyocamycin inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of CASP1 protein]

NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383

G

interleukin 1 beta

multiple interactions

Toyocamycin inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of IL1B protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

NLR family, pyrin domain containing 3

multiple interactions

Toyocamycin inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of NLRP3 protein]

NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811

G

PTEN induced kinase 1

multiple interactions

Toyocamycin inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of PINK1 protein]

NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635

G

X-box binding protein 1

multiple interactions

Toyocamycin inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of XBP1 protein alternative form]

NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	19880
chemical entity	19878
atom	19878
nonmetal atom	19800
nitrogen atom	18979
nitrogen molecular entity	18979
organonitrogen compound	18833
organonitrogen heterocyclic compound	18153
pyrrolopyrimidine	223
((2S,3aS,4R,6S)-4-(hydroxymethyl)-6-(4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-7-yl)tetrahydrofuro[3,4-d][1,3]dioxol-2-yl)methylphosphonic acid	0
(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol 5-phosphate	0
(2R)-1-[(5,6-diphenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]propan-2-ol	0
(2R)-3-\{[(4Z)-5,6-diphenyl-6,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-ylidene]amino\}propane-1,2-diol	0
(2S)-1-[(8aR)-hexahydropyrrolo[1,2-a]pyrimidin-1(2H)-yl]-4-methylpentan-2-amine	0
(2S)-2-[(\{4-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]phenyl\}carbonyl)amino]-4-(2H-tetrazol-5-yl)butanoic acid	0
(2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol	0
(3R,4R)-1-[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]-4-(hydroxymethyl)pyrrolidin-3-ol	0
(3R,4S)-1-[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]-4-[(cyclohexylthio)methyl]pyrrolidin-3-ol	0
(3R,4S)-1-[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]-4-[(methylsulfanyl)methyl]pyrrolidin-3-ol	0
(3S,4R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-[(methylsulfanyl)methyl]pyrrolidine-3,4-diol	0
1,5-diazabicyclo[4.3.0]-non-5-ene	0
1-\{4-[4-amino-5-(3-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]benzyl\}piperidin-4-ol	0
2-(1,3-dimethyl-2,4,6-trioxo-5,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)-N-(2-methoxyphenyl)acetamide	0
2-[[2-(2-ethyl-1-piperidinyl)-2-oxoethyl]thio]-3-methyl-5H-pyrimido[5,4-b]indol-4-one	0
2-amino-3,5-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one	0
2-amino-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one	0
2-amino-4-methoxy-5-cyanopyrrolo[2,3-d]pyrimidine	0
3,4-dihydroxy-2-[(methylsulfanyl)methyl]-5-(4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-7-yl)pyrrolidinium	0
3-[(2-fluorophenyl)methyl]-5-methyl-4-thieno[3,4]pyrrolo[1,3-d]pyrimidinone	0
3-[(4-fluorophenyl)methyl]-5-methyl-4-thieno[3,4]pyrrolo[1,3-d]pyrimidinone	0
3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1-pyrazolyl]propanenitrile	0
3-hydroxy-4-hydroxymethyl-1-(4-oxo-4,4a,5,7a-tetrahydro-3H-pyrrolo[3,2-d]pyrimidin-7-ylmethyl)pyrrolidinium	0
5-(5-chloro-1H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine	0
6-\{4-[(4-ethylpiperazin-1-yl)methyl]phenyl\}-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine +	0
7,8-Dihydro-3-methylpyrrolo[1,2-a]pyrimidin-2(6H)-one	0
7-Carboxy-7-carbaguanine	0
7-Deaza-2'-deoxyguanosine	0
7-aminomethyl-7-deazaguanine	0
7-carboxy-7-deazaguanine +	0
7-cyano-7-deazaguanine	0
7-formamidino-7-deazaguanine +	0
7-pyridin-2-yl-N-(3,4,5-trimethoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine	0
9-deazahypoxanthine	0
GSK2656157	12
GWARJD14	0
LSM-16748	0
LSM-17257	0
LSM-18936	0
LSM-24201	0
LSM-32669	0
LSM-33192	0
N-(\{4-[2-(2-amino-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]phenyl\}carbonyl)-L-glutamic acid	0
N-(\{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]phenyl\}carbonyl)-L-glutamic acid	0
N-(\{4-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]phenyl\}carbonyl)-L-gamma-glutamyl-L-gamma-glutamyl-L-gamma-glutamylglutamic acid	0
N-(\{4-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]phenyl\}carbonyl)-L-valine	0
N-glycosylpyrrolopyrimidine +	21
PF-956980	4
RK-24466	0
[(2R,3R,4S,5S)-5-(2-amino-4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-7-yl)-3,4-dihydroxypyrrolidin-2-yl]methyl dihydrogen phosphate	0
antalarmin	6
baricitinib	9
batzelladine A	0
batzelladine B	0
capivasertib	11
delgocitinib	0
epoxyqueuine	0
immucillin G	0
immucillin H	0
mirodenafil	0
pemetrexed	37
pevonedistat	43
queuine +	0
ritlecitinib	0
ruxolitinib +	53
tofacitinib +	87
vibegron	0
Path 2
Term	Annotations
CHEBI ontology	19880
subatomic particle	19878
composite particle	19878
hadron	19878
baryon	19878
nucleon	19878
atomic nucleus	19878
atom	19878
main group element atom	19817
p-block element atom	19817
p-block molecular entity	19817
carbon group molecular entity	19757
organic molecular entity	19754
organic molecule	19706
organic cyclic compound	19495
organic heterocyclic compound	18874
organic heteropolycyclic compound	18300
organic heterobicyclic compound	17242
pyrrolopyrimidine	223
((2S,3aS,4R,6S)-4-(hydroxymethyl)-6-(4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-7-yl)tetrahydrofuro[3,4-d][1,3]dioxol-2-yl)methylphosphonic acid	0
(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol 5-phosphate	0
(2R)-1-[(5,6-diphenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]propan-2-ol	0
(2R)-3-\{[(4Z)-5,6-diphenyl-6,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-ylidene]amino\}propane-1,2-diol	0
(2S)-1-[(8aR)-hexahydropyrrolo[1,2-a]pyrimidin-1(2H)-yl]-4-methylpentan-2-amine	0
(2S)-2-[(\{4-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]phenyl\}carbonyl)amino]-4-(2H-tetrazol-5-yl)butanoic acid	0
(2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol	0
(3R,4R)-1-[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]-4-(hydroxymethyl)pyrrolidin-3-ol	0
(3R,4S)-1-[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]-4-[(cyclohexylthio)methyl]pyrrolidin-3-ol	0
(3R,4S)-1-[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]-4-[(methylsulfanyl)methyl]pyrrolidin-3-ol	0
(3S,4R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-[(methylsulfanyl)methyl]pyrrolidine-3,4-diol	0
1,5-diazabicyclo[4.3.0]-non-5-ene	0
1-\{4-[4-amino-5-(3-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]benzyl\}piperidin-4-ol	0
2-(1,3-dimethyl-2,4,6-trioxo-5,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)-N-(2-methoxyphenyl)acetamide	0
2-[[2-(2-ethyl-1-piperidinyl)-2-oxoethyl]thio]-3-methyl-5H-pyrimido[5,4-b]indol-4-one	0
2-amino-3,5-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one	0
2-amino-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one	0
2-amino-4-methoxy-5-cyanopyrrolo[2,3-d]pyrimidine	0
3,4-dihydroxy-2-[(methylsulfanyl)methyl]-5-(4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-7-yl)pyrrolidinium	0
3-[(2-fluorophenyl)methyl]-5-methyl-4-thieno[3,4]pyrrolo[1,3-d]pyrimidinone	0
3-[(4-fluorophenyl)methyl]-5-methyl-4-thieno[3,4]pyrrolo[1,3-d]pyrimidinone	0
3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1-pyrazolyl]propanenitrile	0
3-hydroxy-4-hydroxymethyl-1-(4-oxo-4,4a,5,7a-tetrahydro-3H-pyrrolo[3,2-d]pyrimidin-7-ylmethyl)pyrrolidinium	0
5-(5-chloro-1H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine	0
6-\{4-[(4-ethylpiperazin-1-yl)methyl]phenyl\}-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine +	0
7,8-Dihydro-3-methylpyrrolo[1,2-a]pyrimidin-2(6H)-one	0
7-Carboxy-7-carbaguanine	0
7-Deaza-2'-deoxyguanosine	0
7-aminomethyl-7-deazaguanine	0
7-carboxy-7-deazaguanine +	0
7-cyano-7-deazaguanine	0
7-formamidino-7-deazaguanine +	0
7-pyridin-2-yl-N-(3,4,5-trimethoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine	0
9-deazahypoxanthine	0
GSK2656157	12
GWARJD14	0
LSM-16748	0
LSM-17257	0
LSM-18936	0
LSM-24201	0
LSM-32669	0
LSM-33192	0
N-(\{4-[2-(2-amino-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]phenyl\}carbonyl)-L-glutamic acid	0
N-(\{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]phenyl\}carbonyl)-L-glutamic acid	0
N-(\{4-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]phenyl\}carbonyl)-L-gamma-glutamyl-L-gamma-glutamyl-L-gamma-glutamylglutamic acid	0
N-(\{4-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]phenyl\}carbonyl)-L-valine	0
N-glycosylpyrrolopyrimidine +	21
PF-956980	4
RK-24466	0
[(2R,3R,4S,5S)-5-(2-amino-4-oxo-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-7-yl)-3,4-dihydroxypyrrolidin-2-yl]methyl dihydrogen phosphate	0
antalarmin	6
baricitinib	9
batzelladine A	0
batzelladine B	0
capivasertib	11
delgocitinib	0
epoxyqueuine	0
immucillin G	0
immucillin H	0
mirodenafil	0
pemetrexed	37
pevonedistat	43
queuine +	0
ritlecitinib	0
ruxolitinib +	53
tofacitinib +	87
vibegron	0

paths to the root